SEGMENT REPORTING - Additional disaggregated significant segment expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Jun. 30, 2026 |
Mar. 31, 2026 |
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| SEGMENT REPORTING | ||||||||
| Segment Loss | $ 30,070 | $ 7,020 | $ 6,050 | $ 7,462 | $ 6,334 | $ 5,332 | $ 43,140 | $ 19,128 |
| Clinical development | ||||||||
| SEGMENT REPORTING | ||||||||
| Other Segment Items | (980) | (331) | (1,367) | (802) | ||||
| Segment Loss | $ 30,070 | $ 7,462 | $ 43,140 | $ 19,128 | ||||
| Description of other segment items | Other Segment Items included in net loss include finance income. | Other Segment Items included in net loss include finance income. | Other Segment Items included in net loss include finance income. | Other Segment Items included in net loss include finance income. | ||||
| Clinical development | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | ||||||||
| SEGMENT REPORTING | ||||||||
| Employee Expenses | $ 672 | $ 472 | $ 1,841 | $ 1,446 | ||||
| Professional Fees | 2,285 | 1,116 | 4,979 | 4,118 | ||||
| Insurance and other | 722 | 432 | 1,526 | 1,326 | ||||
| Clinical development | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | ||||||||
| SEGMENT REPORTING | ||||||||
| Employee Expenses | 2,804 | 1,635 | 6,832 | 4,991 | ||||
| Clinical Trial Expenses | 2,221 | 1,736 | 5,388 | 4,377 | ||||
| Manufacturing | 545 | 402 | 2,140 | 1,234 | ||||
| License Fees | $ 21,801 | $ 2,000 | $ 21,801 | $ 2,438 | ||||
| X | ||||||||||
- Definition Amount of expense for clinical trial expenses. No definition available.
|
| X | ||||||||||
- Definition The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production, and others. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate costs incurred in the production of goods for sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Description of composition of other segment item not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|